In vivo generated human CAR T cells eradicate tumor cells

Chimeric antigen receptor (CAR) T cells are in prime focus of current research in cancer immunotherapy. Facilitating CAR T cell generation is among the top goals. We have recently demonstrated direct in vivo generation of human CD19-CAR T cells by targeting CD8(+) cells using lentiviral vectors (LVs). The anti-tumor potency of in vivo generated CAR T cells was assessed in human PBMC-transplanted NSG mice carrying i.v. injected CD19(+) Nalm-6 tumor cells. A single injection of CD8-targeted LV delivering CD19-CAR was sufficient to completely eliminate the tumor cells from bone marrow and spleen, whereas control animals contained high levels of CD19(+) cells. Tumor elimination was due to in vivo generated CAR(+) cells. Notably, these were not only composed of T lymphocytes but also included CAR(+) natural killer cells (NK and NKT). This is the first demonstration of tumor elimination by in vivo generated human CAR T cells.